Clinical TrialsProcessa Pharmaceuticals is conducting a Phase 2 trial evaluating NGC-Cap for the treatment of advanced or metastatic breast cancer, which builds upon positive Phase 1b results.
Financial PerformanceProcessa completed a $5M public offering, which is believed to be sufficient to fund the company into 2H25.
Licensing DealProcessa has signed a binding term sheet with Intact Therapeutics, granting an exclusive option to license PCS12852 and is eligible for up to $454M in milestone payments, a 12% royalty, and a 3.5% equity stake.